Scottsdale, Ariz.—May 30, 2017 –Amendola Communications, an award-winning healthcare marketing and public relations agency, announced today that Bridge Therapeutics, Inc., has selected Amendola as its agency of record. Bridge Therapeutics, an innovative development-stage specialty pharmaceutical company, will be pursuing FDA and European Medicines Agency (EMA) approval of a patented (U.S. Patent #8410092) novel drug combination for the treatment of chronic pain in opioid-experienced patients.
Bridge selected Amendola after a rigorous agency review process. Amendola will provide a broad range of public relations and thought leadership services that promote Bridge Therapeutics as a pioneer and innovator in improving the lives of patients living with chronic pain through safer, more effective, and less addictive pain management.
Bridge Therapeutics’ investigational drug compound BT-205 is a unique combination of two synergistic chronic pain drugs—the partial-agonist opioid buprenorphine and the NSAID meloxicam—delivered in a state-of-the-art sublingual formulation. BT-205 is being developed to replace dangerous, full-agonist opioid-based drugs with a safer and more effective medication.
“We are excited that Amendola Communications will help us to bring our message about safer approaches to those struggling with chronic pain and addiction to the market,” said Alton Kelley, director of business development for Bridge Therapeutics. “Chronic pain affects more 100 million Americans today, which the Institutes of Medicine report is more than diabetes, heart disease and cancer combined. As we go through the FDA and EMA approval and commercialization process, we look forward to partnering with Amendola to help us educate the market about the benefits of replacing dangerous opioid-based drugs with a safer and more effective therapy for those struggling with chronic pain and addiction.”
BT-205 has the potential to be a new treatment option for healthcare providers around the world, and to offer patients an alternative chronic pain therapy. When dosed as a combination drug, buprenorphine and meloxicam have stronger pain relief effects, which allows the use of low dosage strengths of both and reduces the potential for negative side-effects.
Amendola Communications will provide targeted strategic public relations services, including media research, media relations, and the generation of top-tier awards and speaking opportunities. The agency will also be responsible for delivering a range of content demonstrating the thought leadership and expertise of Bridge Therapeutics’ key opinion leaders (KOLs), including bylined articles, poster presentations, press releases and other materials.
“Bridge Therapeutics offers an exciting and innovative approach to addressing the opioid addiction crisis facing our nation today,” said Jodi Amendola, CEO of Amendola Communications. “Addictive chronic pain drugs today kill more Americans than road crashes, and yet the massive chronic pain market in the United States still lacks a non-addictive pain medication. We look forward to promoting Bridge Therapeutics and its key opinion leaders as the company continues to go through its regulatory approval and commercialization process.”
About Amendola Communications
Amendola Communications is an award-winning national public relations, marketing communications, social media and content marketing firm. Named one of the best information technology (IT) PR firms in the nation four times by PRSourceCode, Amendola represents some of the best-known brands and groundbreaking startups in the healthcare and HIT industries. Amendola’s seasoned team of PR and marketing pros delivers strategic guidance and effective solutions to help organizations boost their reputation and drive market share. For more information about the PR industry’s “A Team,” visit www.acmarketingpr.com, and follow Amendola on Twitter and LinkedIn.
About Bridge Therapeutics
Bridge Therapeutics®, based in Birmingham, Ala., is an innovative development-stage specialty pharmaceutical company pursuing U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals of a patented (U.S. Patent #8410092) drug combination, BT-205, for the treatment of chronic pain in opioid-experienced patients. The investigational drug BT-205 is a unique combination of two synergistic chronic pain drugs—the partial-agonist opioid buprenorphine and the NSAID meloxicam—delivered in a state-of-the-art sublingual formulation. The dosing and delivery method will be a commercial advantage over the current alternatives. Bridge Therapeutics’ goal is to make the BT-205 compound and other investigational new drug candidates available to millions of patients in which addictive and potentially dangerous full-agonist opioids such as oxycodone and morphine are ineffective and/or unsatisfactory. The company is focused on improving the lives of patients living with chronic pain by developing new approaches to pain management that are safer, more effective, and less addictive. For more information, visit www.bridgetherapeutics.com.
Media Contact: Tara Stultz | 440.225.9595 | email@example.com